Aerovate Therapeutics Stock Net Asset
| AVTE Stock | USD 17.09 0.04 0.23% |
Aerovate Therapeutics fundamentals help investors to digest information that contributes to Aerovate Therapeutics' financial success or failures. It also enables traders to predict the movement of Aerovate Stock. The fundamental analysis module provides a way to measure Aerovate Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aerovate Therapeutics stock.
Aerovate | Net Asset |
Aerovate Therapeutics Company Net Asset Analysis
Aerovate Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Aerovate Therapeutics Net Asset | 127.42 M |
Most of Aerovate Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aerovate Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aerovate Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Aerovate Therapeutics is extremely important. It helps to project a fair market value of Aerovate Stock properly, considering its historical fundamentals such as Net Asset. Since Aerovate Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aerovate Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aerovate Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Aerovate Total Assets
Total Assets |
|
Based on the recorded statements, Aerovate Therapeutics has a Net Asset of 127.42 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Aerovate Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aerovate Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aerovate Therapeutics could also be used in its relative valuation, which is a method of valuing Aerovate Therapeutics by comparing valuation metrics of similar companies.Aerovate Therapeutics is currently under evaluation in net asset category among related companies.
Aerovate Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aerovate Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aerovate Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aerovate Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aerovate Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aerovate Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aerovate Therapeutics' value.| Shares | Octagon Capital Advisors Lp | 2024-03-31 | 403.7 K | Geode Capital Management, Llc | 2023-12-31 | 276.9 K | Ghost Tree Capital, Llc | 2024-03-31 | 225 K | State Street Corporation | 2023-12-31 | 214 K | Nantahala Capital Management, Llc | 2023-12-31 | 182.4 K | Paradigm Biocapital Advisors Lp | 2023-12-31 | 143.2 K | Ensign Peak Advisors Inc | 2023-12-31 | 122.3 K | Hudson Bay Capital Management Lp | 2023-12-31 | 103 K | Northern Trust Corp | 2023-12-31 | 99.5 K | Ra Capital Management, Llc | 2023-12-31 | 8.3 M | Sofinnova Ventures | 2023-12-31 | 3.8 M |
Aerovate Fundamentals
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 393.77 M | ||||
| Shares Outstanding | 28.81 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 99.97 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 6.43 X | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash And Equivalents | 151.99 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 675 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.85 X | ||||
| Book Value Per Share | 3.26 X | ||||
| Cash Flow From Operations | (56.78 M) | ||||
| Short Ratio | 11.77 X | ||||
| Earnings Per Share | (3.03) X | ||||
| Target Price | 44.67 | ||||
| Number Of Employees | 51 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 492.33 M | ||||
| Total Asset | 127.42 M | ||||
| Retained Earnings | (163.42 M) | ||||
| Working Capital | 106.59 M | ||||
| Net Asset | 127.42 M |
About Aerovate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aerovate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerovate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerovate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Aerovate Therapeutics Piotroski F Score and Aerovate Therapeutics Altman Z Score analysis. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Aerovate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.03) | Return On Assets (0.48) | Return On Equity (0.81) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.